ERBB2 and cancer: Unlike the co-treatment of unmodified NK cells with therapeutic antibodies, which showed a low anti-cancer effect in both HER2-positive and Trop-2 positive cells, the co-treatment of AC-NKs with a therapeutic antibody such as trastuzumab (TZ), trastuzumab-emtansine (T-DM1), and Sacituzumab (SZ) improved their anti-cancer efficacy in HER2-positive and Trop-2 positive cells.